Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation

Introduction Immune checkpoint inhibitors have demonstrated the benefit for many cancer types, melanoma, non-small cell lung cancer, urothelial cancer, renal cell cancer, etc. Especially in advanced non-small cell lung cancer, significant improvement in survival results has been shown. Case Report H...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2020-12, Vol.26 (8), p.2042-2046
Main Authors: Sengul Samanci, Nilay, Yılmaz, Umut, Bedir, Sahin, Ozgur Yurttas, Nurgul, Oruc, Kerem, Durak Sahin, Zehra, Celik, Emir, Toplutas, Kubra Nur, Akı, Hilal, Eskazan, Ahmet Emre, Demirelli, Fuat Hulusi
Format: Article
Language:English
Subjects:
Adenocarcinoma
Aged
Bladder cancer
Carcinoma, Non-Small-Cell Lung - drug therapy
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - adverse effects
Immunotherapy
Kidney cancer
Lung cancer
Lung Neoplasms - drug therapy
Lymphoma
Lymphoma, Follicular - chemically induced
Male
Melanoma
Monoclonal antibodies
Nivolumab - adverse effects
Non-small cell lung carcinoma
Pneumonitis
Renal cell carcinoma
Respiratory failure
Small cell lung carcinoma
Targeted cancer therapy
Urothelial cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Immune checkpoint inhibitors have demonstrated the benefit for many cancer types, melanoma, non-small cell lung cancer, urothelial cancer, renal cell cancer, etc. Especially in advanced non-small cell lung cancer, significant improvement in survival results has been shown. Case Report Here, we report a 66-year-old man with lung adenocarcinoma who received nivolumab for 80 cycles. Management and Outcome: Two months after discontinuing nivolumab, he developed follicular lymphoma. Pneumonitis was also accompanied, which was treated with metilprednisolon, but he died due to progressive respiratory failure. Discussion Our clinical knowledge with checkpoint inhibitors is increasing day by day, and to the best of our knowledge, this paper presents the first case in the English literature who developed follicular lymphoma after discontinuing nivolumab in non-small cell lung cancer patient.
ISSN:1078-1552
1477-092X
DOI:10.1177/1078155220918627